ライフサイエンスコーパス: PDT

1 which is exploited in photodynamic therapy (PDT).

2 totoxic therapy called photodynamic therapy (PDT).

3 ) and 7 investigating psychodynamic therapy (PDT).

4 rared (NIR) two-photon photodynamic therapy (PDT).

5 zumab; ranibizumab; or photodynamic therapy (PDT).

6 (PPIX) accumulation in photodynamic therapy (PDT).

7 of great interest for photodynamic therapy (PDT).

8 (2PLM) and two-photon photodynamic therapy (PDT).

9 ships for their use in photodynamic therapy (PDT).

10 ctive chemotherapy and photodynamic therapy (PDT).

11 desired for antitumor photodynamic therapy (PDT).

12 as photosensitizers in photodynamic therapy (PDT).

13 tal photochemistry and photodynamic therapy (PDT).

14 study than animals treated with RB-mediated PDT.

15 eyes at baseline and at 1- and 3-months post-PDT.

16 oxic singlet oxygen to significantly enhance PDT.

17 to be targeted to tumors, for X-ray-induced PDT.

18 n (TBP) ligands, for hypoxia-tolerant type I PDT.

19 ted the therapeutic success of the delivered PDT.

20 greatly enhanced the efficacies of RT and/or PDT.

21 , which ensured its effective imaging-guided PDT.

22 ed further development and clinical usage of PDT.

23 d pain associated with microneedle expedited PDT.

24 anotechnology-based photosensitizers used in PDT.

25 y to develop CSCR recurrence after half-dose PDT.

26 ght eyes (5.9%) had complications related to PDT.

27 ays, alleviating the aerobic requirement for PDT.

28 t of ALA-induced PpIX in cancer cells during PDT.

29 sitizer-MnO2 nanosystem for highly efficient PDT.

30 ed curettage followed by aminolevulinic acid PDT.

31 , function and resource use for both CBT and PDT.

32 s a potential means of the (1) O2 control in PDT.

33 ribed choroidal hemangioma were treated with PDT.

34 d recurrence rate of CSCR at 36 months after PDT.

35 ting energy transfer-based (1) O2 controlled PDT.

36 ediate to poor visual acuity (<=20/50) after PDT.

37 ding their potential as pH-controlled PS for PDT.

38 of a targeted PDT agent for IGS and adjuvant PDT.

39 the efficacy of reduced and standard-fluence PDT.

40 a promising nanoplatform for enhanced cancer PDT.

41 ed with standard-fluence and reduced-fluence PDT.

42 e, lack of CME, and lack of treatment before PDT.

43 performance as a triplet photosensitizer for PDT.

44 ide a new insight into the design of precise PDT.

45 gon laser photocoagulation (42.1% vs. 0.4%), PDT (0% vs. 43.8%), transpupillary thermotherapy (0% vs.

46 prodrug to achieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or bot

47 Predominantly daytime (pDT) (0700-1859; n = 282) and predominantly nighttime (p

48 by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.

49 tumors were treated with a single session of PDT, 11 tumors received 2 sessions, 1 tumor received 3 s

50 At 36 months after PDT, 132 eyes (97.1%) achieved complete resolution of SR

51 Comparison of hemangioma managed in the pre-PDT (1967-2001) era versus PDT (2002-2018) era.

52 lvated microporous framework Cu[Ni(pdt)(2)] (pdt(2-) = 2,3-pyrazinedithiolate), and find that the con

53 nitrile-solvated microporous framework Cu[Ni(pdt)(2)] (pdt(2-) = 2,3-pyrazinedithiolate), and find th

54 anaged in the pre-PDT (1967-2001) era versus PDT (2002-2018) era.

55 imiquimod (53.9%; 95% CI, 45.4 to 61.6), MAL-PDT (37.7%; 95% CI, 30.0 to 45.3), or ingenol mebutate (

56 rgeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or both V- and C-PDT (9 h).

57 PDT (660-nm light) was carried out against S. mutans bio

58 llular targeted-PDT, 48 h), or both V- and C-PDT (9 h).

59 e some physicochemical factors that can make PDT a more viable and effective option to provide future

60 Photodynamic therapy (PDT), a treatment that uses a photosensitizer, molecular

61 pite excellent healing of the oral mucosa in PDT, a lack of robust enabling technology for intraoral

62 The ISC process is turned off to deactivate PDT ability, when the PS is transferred or metabolized a

63 intained follow-up (40 eyes, 45 tumors), and PDT achieved tumor control with 1 session (n = 32 tumors

64 549) to test their photodynamic therapeutic (PDT) activity.

65 Crossover to half-dose PDT after previous unsuccessful HSML treatment for cCSC

66 blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans biofilms.

67 y was to determine the utility of a targeted PDT agent for IGS and adjuvant PDT.

68 3 transformed TiO2 from a dual type I and II PDT agent to a predominantly type I photosensitizer, irr

69 te-specific membrane antigen (PSMA)-targeted PDT agent, PSMA-1-Pc413, we showed that PSMA-1-Pc413 sel

70 nsition metal complexes are highly promising PDT agents due to intense visible light absorption, yet

71 a intra-tumoral injection could prolong both PDT agents retention in tumor.

72 ng recent developments of nanoparticle-based PDT agents, their combinations with different drugs, des

73 ison of clinical features for tumor control (PDT alone vs. PDT plus additional therapy) revealed thos

74 onal therapy) revealed those controlled with PDT alone were more likely to be adenocarcinoma (73% vs.

75 al chemotherapy, showed better efficacy than PDT alone, without systemic side effects.

76 Thirty-two patients received PDT and 10 patients received HSML.

77 ieved complete resolution of SRD with single PDT and 4 eyes (2.9%) had CSCR recurrence.

78 s and 81 eyes with chronic CSCR treated with PDT and 64 untreated fellow eyes were evaluated.

79 onstrate that combination of single low-dose PDT and a subclinical dose of nanoliposomal irinotecan s

80 uding subretinal fluid, were recorded before PDT and during follow-up examinations.

81 key requirement for the generation of ROS in PDT and given the fact that hypoxia is a characteristic

82 pportunities for the clinical translation of PDT and irinotecan combination therapy for effective pan

83 prodrug, exhibiting the combined effects of PDT and local chemotherapy, showed better efficacy than

84 cancer cells through the combined effects of PDT and locally released PTX.

85 s have emerged as promising systems for both PDT and PCT.

86 Both MN-assisted PDT and PTT are light-mediated phototherapy methods and

87 cancer cells through the combined effects of PDT and site-specific PTX chemotherapy.

88 D viability imaging revealed synergy between PDT and the standard-of-care chemotherapeutic carboplati

89 ing a particular type of photoreactivity for PDT and/or PCT effects.

90 apies: (1) verteporfin photodynamic therapy (PDT) and (2) anti-vascular endothelial growth factor (VE

91 ted against several dermatological diseases (PDT) and (antibiotic-resistant) pathogenic microorganism

92 ed to perform in vitro photodynamic therapy (PDT) and diagnostic assays for treatment assessment on a

93 to the progression of photodynamic therapy (PDT) and microbial photodynamic inactivation (PDI) in cl

94 on metal complexes for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT), and discuss

95 y strategies including photodynamic therapy (PDT) and photothermal therapy (PTT) to treat many diseas

96 y enabling immunogenic photodynamic therapy (PDT) and promoting the maturation of dendritic cells (DC

97 The combination of photodynamic therapy (PDT) and radiation therapy (RT) more significantly inhib

98 o efficient probes for photodynamic therapy (PDT) and stochastic optical reconstruction microscopy (S

99 as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT).

100 s, and sensitizers for photodynamic therapy (PDT); and more recently as models for aromaticity (both

101 quimod, 2.73 (95% CI, 1.87 to 3.99) with MAL-PDT, and 3.33 (95% CI, 2.29 to 4.85) with ingenol mebuta

102 both the advantages of radiotherapy (RT) and PDT, and has considerable potential applications in clin

103 ry/release, near-infrared (NIR)-excited deep PDT, and radiosensitization, respectively, all of which

104 In conclusion, both CBT and PDT appear to potentially offer some benefit for FND, al

105 ficance of this PS for mitochondria targeted PDT applications in deep tissue cancer therapy.

106 2; dose rate, 600 mW/cm2; wavelength, 689 nm PDT applied to the treatment eye for 42 s).

107 2; dose rate, 600 mW/cm2; wavelength, 689 nm PDT applied to the treatment eye for 83 s) and reduced-f

108 ntional photosensitisers used clinically for PDT are ineffective for photochemical internalisation ow

109 gen greatly hinders the broad application of PDT as a first-line cancer treatment option.

110 Overall, our approach potentiates PDT as a viable therapeutic option for early stage oral

111 patient and a hindrance to widespread use of PDT as standard field therapy for AK.

112 umor xenografts immediately before and after PDT at different time points.

113 ic CSCR are recommended to undergo half-dose PDT before they have significant visual deterioration.

114 ients with chronic CSCR undergoing half-dose PDT between 2005 and 2011 were reviewed.

115 R in the no-treatment, photodynamic therapy (PDT), bevacizumab, and ranibizumab groups, respectively.

116 ly promising for smart photodynamic therapy (PDT), but achieving this goal remains a tremendous chall

117 t oxygen ((1)O(2)) for photodynamic therapy (PDT), but also triggers a spontaneous cascade reaction t

118 describe a treatment strategy that combines PDT by a new chlorin-based nanoscale metal-organic frame

119 2 ](+) or [Ru(bpy)3 ](2+) moieties to induce PDT by generating reactive oxygen species (ROS).

120 hich is different from photodynamic therapy (PDT) by the use of highly penetrating acoustic waves to

121 Chronic CSCR patients treated with half-dose PDT can achieve long-term stable visual acuity and resol

122 rous tumours, treating hypoxic tumours using PDT can be a challenge.

123 findings indicate that nanoparticle-mediated PDT can potentiate the systemic efficacy of checkpoint b

124 However, oxygen consumption during PDT can result in an inadequate oxygen supply which redu

125 Photodynamic therapy (PDT) can destroy local tumors and minimize normal tissue

126 With PDT, Ce6-SCs demonstrate high singlet oxygen generation

127 ieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or both V- and C-PDT

128 serous retinal detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), a

129 X-ray-induced photodynamic therapy (X-PDT) combines both the advantages of radiotherapy (RT) a

130 mediated by IYIY-I2-BODIPY in pre- and post-PDT conditions.

131 ugs killed cancer cells surviving from rapid PDT damage via bystander effects.

132 nts, while crossover to HSML after half-dose PDT does not seem to significantly affect these endpoint

133 ctors now viewed as critical determinates of PDT dose, efficacy, and toxicity, that study showed rema

134 es iridium corroles particularly exciting as PDT drug candidates.

135 However, the efficiency of existing PDT drug molecules in the deep-tissue-penetrable near-in

136 lexes utilize blue or UV-A light to obtain a PDT effect, limiting the penetration depth inside tissue

137 conjugated photosensitizers, resulting in a PDT effect.

138 induces tumor hypoxia, thereby weakening the PDT effect.

139 pigmented posterior choroidal melanoma with PDT effectively preserves visual acuity, 5-year treatmen

140 20 nm, 100 J/cm(2), 160 mW/cm(2)) to produce PDT effects (drug-light interval 1 h), IYIY-I2-BODIPY in

141 les show superior tumor-targeted therapeutic PDT effects against cancer cells both in vitro and in vi

142 DLI), and to investigate the impact of rapid PDT effects on the pharmacokinetic (PK) profiles of the

143 rious microfluidic Lab-on-a-chip systems for PDT efficacy analysis on 3D culture and discusses micros

144 nd accumulating in tumors, and enhancing the PDT efficacy with a tumor growth inhibition of 96.0%.

145 MOF nanoparticle formulation showed enhanced PDT efficacy with superior (1) O2 control compared to th

146 thermal effect of Au@Rh-ICG-CM also improves PDT efficacy.

147 o address tumor hypoxia while achieving high PDT efficacy.

148 Photodynamic therapy (PDT) efficacy is limited by the very short half-life and

149 it could be shown that photodynamic therapy (PDT) elevates antitumor immune responses.

150 nerating four distinct ROSs, Ti-TBP-mediated PDT elicits superb anticancer efficacy with >98% tumor r

151 ns new avenues of particle expansion-induced PDT enhancement by controlled imidazole chemistry.

152 After treatment, patients in the PDT era demonstrated better mean logarithm of the minimu

153 Management of choroidal hemangioma in the PDT era has allowed for significantly better visual outc

154 220 cases] vs. PDT [n = 238 cases]) revealed PDT era patients were of older mean age (48.9 vs. 53.8 y

155 with mean final visual acuity of 20/400 (pre-PDT era) versus 20/63 (PDT era).

156 acuity of 20/400 (pre-PDT era) versus 20/63 (PDT era).

157 better visual outcome compared with the pre-PDT era, with mean final visual acuity of 20/400 (pre-PD

158 ic index and extend the spectrum of clinical PDT far beyond what was imagined when that sentinel manu

159 Compared with pDT feeding, pNT feeding was associated with a higher BA

160 After PDT for chronic CSCR we observed sustained reductions in

161 The utilization of photodynamic therapy (PDT) for the treatment of various types of cancer has ga

162 Subsequent PDT further reduced tumor recurrence and extended animal

163 etinal fluid (evaluation visit: 1:48% in the PDT group and 16% in the HSML group, P = .002; final vis

164 etinal fluid (evaluation visit 1: 57% in the PDT group and 17% in the HSML group, P = .007; final vis

165 eks after treatment), 81% of patients in the PDT group had complete resolution of SRF, while none of

166 The mean retinal sensitivity in the PDT group increased from 21.7 dB (standard error [SE]: 0

167 Since its publication, PDT has been increasingly utilized in clinical practice

168 We believe that nMOF-enabled PDT has the potential to significantly enhance checkpoin

169 Photodynamic therapy (PDT) has been applied in cancer treatment by utilizing r

170 In recent years photodynamic therapy (PDT) has received widespread attention in cancer treatme

171 Photodynamic therapy (PDT) holds great promise for cancer therapy; however, it

172 The exploration of nMOFs in PDT, however, remains limited to an oxygen-dependent typ

173 o overcome some of the limitations of RT and PDT in cancer treatment.

174 Specifically, PDT in conjugation with widely used chemotherapeutic dru

175 mouth props that can be utilized to perform PDT in conscious subjects without the need of extensive

176 -Cy nanoparticles may be good candidates for PDT in deeply seated tumors when combined with X-rays an

177 ly viewed as the starting point for clinical PDT in modern medicine.

178 uence PDT was comparable to standard-fluence PDT in the treatment of PCV in terms of visual gains, cl

179 This limits the utility of PDT in treating hypoxic tumors since lower levels of cyt

180 The viable use of photodynamic therapy (PDT) in cancer therapy has never been fully realized bec

181 s and the discovery of photodynamic therapy (PDT) in the early 1900s, the landmark article in 1978 in

182 Treatment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1% vs. 0.

183 of porphyrin-mediated photodynamic therapy (PDT), including low depths of tissue penetration that re

184 In PDT-induced hypoxia, providing singlet oxygen from store

185 However, PDT-induced tumor hypoxia as a result of oxygen consumpt

186 Measuring and monitoring intrinsic and PDT-induced tumor hypoxia in vivo during PDT is of high

187 ous irradiation during photodynamic therapy (PDT) inevitably induces tumor hypoxia, thereby weakening

188 Moreover, we show that PDT inhibited survivin expression.

189 review summarizes the challenges to bringing PDT into mainstream cancer therapy.

190 n overcoming the difficulty in transitioning PDT into the medical field.

191 This review describes the current status of PDT investigations using microfluidic Lab-on-a-Chip syst

192 a lack of high-quality controlled trials of PDT is a significant limitation, as is the lack of long-

193 However, a limitation of PDT is its dependence on light that is not highly penetr

194 and PDT-induced tumor hypoxia in vivo during PDT is of high interest for prognostic and treatment eva

195 Unfortunately, PDT is often followed by recurrence due to incomplete ab

196 Half-dose PDT is superior to HSML treatment in cCSC patients, rega

197 Photodynamic therapy (PDT) is a clinically approved anti-cancer treatment that

198 Photodynamic therapy (PDT) is a clinically approved therapeutic modality to tr

199 Photodynamic therapy (PDT) is a new strategy for treating local cancers using

200 Photodynamic therapy (PDT) is a promising cancer treatment modality that can s

201 Photodynamic therapy (PDT) is an approved modality for the treatment of variou

202 Photodynamic therapy (PDT) is an effective and cosmetically favorable treatmen

203 Photodynamic therapy (PDT) is an efficacious treatment for some types of cance

204 Photodynamic therapy (PDT) is an important cancer treatment modality due to it

205 Photodynamic therapy (PDT) is an important clinically relevant therapeutic mod

206 mors, oxygen-dependent photodynamic therapy (PDT) is considerably limited.

207 Photodynamic therapy (PDT) is widely used to treat diverse diseases, but its d

208 gy between oxaliplatin and pyrolipid-induced PDT kills tumour cells and provokes an immune response,

209 treatment eye for 83 s) and reduced-fluence PDT (light dose, 25 J/cm2; dose rate, 600 mW/cm2; wavele

210 parison of outcomes between standard-fluence PDT (light dose, 50 J/cm2; dose rate, 600 mW/cm2; wavele

211 A statistically significant improvement in PDT mediated efficacy (p<0.001) was also observed when t

212 cted with such helical bodipy show efficient PDT-mediated antitumor immunity amplification with an ul

213 hese data point to a novel "thiol-blocked" [(PDT)Mo(V)O(S(Cys))(thiolate)](-) structure, which is sup

214 IYIY-I2-BODIPY alone and in combination with PDT modulates the immune response in such a way that tum

215 A comparison (pre-PDT [n = 220 cases] vs. PDT [n = 238 cases]) revealed PD

216 A comparison (pre-PDT [n = 220 cases] vs. PDT [n = 238 cases]) revealed PDT era patients were of o

217 Case-control review of 38 consecutive PDT-naive macular PCV patients who underwent verteporfin

218 l, which is not possible for the counterpart PDT nanoagent.

219 ons in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.

220 aptive modification of light delivery during PDT on a fine scale to optimize treatment response.

221 g and (2) Cherenkov-photodynamic therapy (CR-PDT) on cells could be achieved under conditions mimicki

222 Age, gender, race, use of PDT or focal laser therapy, and central subfield thickne

223 Patients were treated with either half-dose PDT or HSML (both indocyanine green angiography-guided)

224 ed crossover treatment with either half-dose PDT or HSML.

225 MN-assisted PDT or PTT has been studied for various applications by

226 review summarizes recent advances in MNs for PDT or PTT.

227 ibits tumor growth than monotherapies (i.e., PDT or RT).

228 yl aminolevulinate photodynamic therapy (MAL-PDT), or 0.015% ingenol mebutate gel.

229 in tumor environments, improved therapeutic PDT outcomes should be achievable even under hypoxic con

230 t difference in tumor hypoxia in response to PDT over time was found between the U87MG and MDA-MB-435

231 nophotosensitizers for photodynamic therapy (PDT) owing to their high photosensitizer loadings, facil

232 ment in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times).

233 mor-centered approach, as part of a complete PDT package that includes the light component and the pr

234 market and clinical trials that are used in PDT/PDI.

235 al features for tumor control (PDT alone vs. PDT plus additional therapy) revealed those controlled w

236 The optimal PDT protocol remains controversial and it is postulated

237 example of a DFT guided search for efficient PDT PSs with a substantial spectral red shift toward the

238 hat is, multimodal therapy for cancer (e.g., PDT, PTT) and antimicrobial treatment, and eventually in

239 nt tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by controlled drug delivery/rel

240 undred times lower than that of the existing PDT reagents.

241 nolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of targeting AML stem cel

242 o underwent verteporfin PDT using one of two PDT regimens at a tertiary referral centre in an Asian p

243 olyp closure and recurrences between the two PDT regimens.

244 ese results may indicate relatively enhanced PDT response by AFXL pretreatment in diseased skin.

245 LAK)(2) conjugate as a photodynamic therapy (PDT) sensitizer.

246 A total of 116 PDT sessions were performed (mean, 1.5 sessions; range,

247 erapy vs. 5.6 combination therapy; mean, 1.2 PDT sessions), respectively.

248 In eyes receiving PDT, Snellen visual acuity (VA) significantly improved a

249 tervention for cancer, photodynamic therapy (PDT) still suffers from limitations.

250 ial and it is postulated that less intensive PDT strategies may reduce complications.

251 The PDT study revealed significant cytotoxicities of porphyr

252 Although photodynamic therapy (PDT) takes advantage of the spatial-temporal control of

253 Recurrences after PDT tend to occur along the tumor edges, often with mini

254 In PDT, the effective range is limited by the distribution

255 PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness.

256 r photosensitizers for photodynamic therapy (PDT) through the enhanced penetration and retention effe

257 MOLs (ca. 1.2 nm) enable highly effective X-PDT to afford superb anticancer efficacy.

258 , the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial.

259 ) of 49.5 (15.3, 7.0-66.0) months from first PDT to last follow-up.

260 hyrin (TBP) ligands, cationic W-TBP mediates PDT to release tumor associated antigens and delivers im

261 w depths of tissue penetration that restrict PDT to superficial lesions, inability to treat hypoxic t

262 ided surgery (IGS) and photodynamic therapy (PDT) to resect and ablate cancer cells.

263 increase in ETDRS letters was higher in the PDT-treated group when comparing baseline and first eval

264 PDT-treated patients in the focal and diffuse leakage gr

265 at first evaluation and at final visit, more PDT-treated than HSML-treated patients demonstrated a re

266 at first evaluation and at final visit, more PDT-treated than HSML-treated patients showed a resoluti

267 use models further demonstrate that ZnP@pyro PDT treatment combined with anti-PD-L1 results in the er

268 RB-C(KLAKLAK)(2)-mediated PDT treatment of subcutaneous B16-F10-Luc2 tumors in C57

269 mice bearing the same tumours 20min prior to PDT treatment.

270 es had complete SRF resolution after another PDT treatment.

271 cells are subjected to photodynamic therapy (PDT) treatment in the presence of DPP, resulting in atte

272 tral choroid thickness (CCT), mean number of PDT treatments needed, mean number of anti-VEGF injectio

273 ote the development of photodynamic therapy (PDT), undesired side effects like low tumor specificity

274 to provide current information pertaining to PDT use, including a discussion of in vitro and in vivo

275 cular PCV patients who underwent verteporfin PDT using one of two PDT regimens at a tertiary referral

276 Treatment with standard fluence PDT using verteporfin.

277 t harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that localises in endolysos

278 asma/tumor ratio of the prodrug to achieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targ

279 n delivery to tumours, achieve deeper tissue PDT via red-shifted porphyrin Q-bands, energy transfer a

280 lymer (POEGMA-b-P(MAA-co-VSPpaMA) to enhance PDT via the controllable release of photosensitizers.

281 Treatment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1

282 PDT was achieved with Ag NRs using low irradiation (1.4

283 In this comparative analysis, PDT was an effective treatment method for circumscribed

284 Reduced-fluence PDT was comparable to standard-fluence PDT in the treatm

285 Dual-mode imaging and PDT was subsequently performed in tumor-bearing mice.

286 Standard duration PDT was used in most cases (83 seconds; n = 110/116 [95%

287 ers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma membrane-activatable po

288 Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and sho

289 omography (OCT), and recurrence of CSC after PDT were compared between the 2 groups.

290 cumscribed choroidal hemangioma treated with PDT were identified, and factors predictive of final vis

291 arked light source, which is unlike standard PDT, where light penetration depth is limited in biologi

292 se here and demonstrate the concept of smart PDT, where pH-induced reversible twisting maximizes the

293 d cycle of curettage and aminolevulinic acid PDT with resolution.

294 to) aPS was also compatible to near infrared PDT with two photon excitation (800 nm) for extensive bi

295 bstantial risk of treatment failure, primary PDT with vertepofrin is recommended in exceptional cases

296 g combination standard photodynamic therapy (PDT) with intravitreal ranibizumab in the treatment of p

297 w-dose X-ray-induced photodynamic therapy (X-PDT) with negligible side effects.

298 cence imaging (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and

299 Photodynamic therapy (PDT) with protoporphyrin IX (PpIX), which is endogenousl

300 EGF monotherapy and combination therapy with PDT yielded comparable outcomes as those of controlled c